Indian Journal of Medical Research

AUTHORS«SQ» RESPONSE
Year
: 2017  |  Volume : 146  |  Issue : 3  |  Page : 431--432

Authors' Response


Muthuvel Bharathselvi, Sayantan Biswas, Rajiv Raman, Radhakrishnan Selvi, Karunakaran Coral, Angayarkanni Narayanansamy, Sivaramakrishnan Ramakrishnan, Konerirajapuram N Sulochana 
 Department of Biochemistry & Cell Biology, Visual Research Foundation, Sankara Nethralaya, Chennai 600 006, Tamil Nadu, India

Correspondence Address:
Konerirajapuram N Sulochana
Department of Biochemistry & Cell Biology, Visual Research Foundation, Sankara Nethralaya, Chennai 600 006, Tamil Nadu
India




How to cite this article:
Bharathselvi M, Biswas S, Raman R, Selvi R, Coral K, Narayanansamy A, Ramakrishnan S, Sulochana KN. Authors' Response.Indian J Med Res 2017;146:431-432


How to cite this URL:
Bharathselvi M, Biswas S, Raman R, Selvi R, Coral K, Narayanansamy A, Ramakrishnan S, Sulochana KN. Authors' Response. Indian J Med Res [serial online] 2017 [cited 2020 Apr 2 ];146:431-432
Available from: http://www.ijmr.org.in/text.asp?2017/146/3/431/223636


Full Text

We thank Leslie M. Klevay[1] for comments on our article and also for providing an interesting review on the association between copper deficiency and age related eye lesions.

Klevay suggests, based on literary evidence that copper supplementation might help people with ARMD and in general, neuropathies. We endorse that copper deficiency is associated with hyper-homocystemia and oxidative stress[2]. However, it has been seen in patients with ARMD and other retinopathies that circulating copper level is low but their corresponding tissue levels are higher than in normal individuals which indicates that the copper transport and homeostasis may be affected[2],[3]. Copper is proangiogeneic and stimulates vascular endothelial growth factor (VEGF) expression, while use of agents to reduce copper uptake in endothelial cells reverses the condition[4]. Therefore, before advocating copper supplementation, one must know the biochemical mechanism. Why and how does homocysteine (Hcy) influence the intracellular and plasma levels of copper in an individual? In reverse, homocysteine induces cardiac hypertrophy by upregulating expression of ATP7a, a protein, which is responsible for copper efflux[5]. The direct effect of Hcy on copper homeostasis in cardiac cells is that it induces the expression of ATP7a - the efflux chaperone which drains out the copper from the cell and the delivery of copper to superoxide dismutase (SOD) enzyme and cytochrome c oxidase (COX) activity is thus hindered. They have also reported increased serum copper levels in these conditions[5].

The homeostasis mechanism of copper and the effect of Hcy need to be studied with respect to ocular cells and tissues, for example, in retinal pigment epithelial cells (RPE), choroid and retina. We observed a decrease copper levels in plasma of idiopathic retinal vascular diseases[3]. The choroid and retinal tissues showed increased copper accumulation in the ARMD tissues[6] indicating intracellular copper accumulation in ARMD. A study needs to be conducted to understand the effect of varying concentrations of homocysteine on copper uptake and efflux in RPE cells.

The increased Hcy was associated with low levels of copper resulting in decreased (amine oxidase) lysyl oxidase activity in vascular diseases[7]. It is known that increased levels of Hcy chelate copper and impair copper dependent enzymes and further, copper supplementation improves the cardiac function in pressure overload heart failure[7]. Copper chelating peptides are antiangiogenic by restricting copper accumulation inside endothelium[8].

Dong et al[9] showed that homocysteine disturbed copper homeostasis leading to mitochondrial dysfunction and endothelial cell injury.

In short, we need to study more to understand the relationship between copper and Hcy, at the levels of the protein involvement in Hcy pathways, copper transport and homeostasis.

References

1Khevay LM. Ocular lesions from copper deficiency. Indian J Med Res 2017; 146 : 430-1.
2Sulochana KN, Coral K, Punitham R, Sharma T, Kasinathan N, Ramakrishnan S. Trace elements iron, copper and zinc in vitreous of patients with various vitreoretinal diseases. Indian J Opthalmol 2004; 52 : 145-8.
3Gomathy NI, Saravanan R, Bharathselvi M, Biswas J, Sulochana KN. Localization of human copper transporter I in the eye and its role in Eales disease. Ocul Immunol Inflamm 2016; 24 : 678-683.
4Gomathy N, Bharathidevi SR, Harish V, Bharathselvi M, Sulochana K.N. CTR1 silencing inhibits angiogenesis by limiting copper entry in endothelial cells. Plos One 2013; 8 : e71982.
5Cao Z, Zhang Y, Sun T, Zhang S, Yu W, Zhu J. Homocysteine induces cardiac hypertrophy by upregulating ATP7a expression. Int J Clin Exp Pathol 2015; 8 : 12829-36.
6Flinn JM, Kakalec P, Tappero R, Jonesc B, Lengyel I. Correlations in distribution and concentration of calcium, copper and iron with zinc in isolated extracellular deposits associated with age-related macular degeneration. Metallomics 2014; 6 : 1223-8.
7Hughes WM, Rodriguez WE, Rosenberger D, Chen J, Sen U, Tyagi N, et al. Role of copper and homocysteine in pressure overload heart failure. Cardiovasc Toxicol 2008; 8 : 137-44.
8Arun M, Bhuvanasundar R, Coral K, Subbulakshmi C, Sulochana KN. Peptides derived from the copper binding region of lysyl oxidase exhibit antiangiogeneic properties by inhibiting enzyme activity: An in vitro study. J Pept Sci 2014; 20 : 837-49.
9Dong D, Wang B, Yin W, Ding X, Yu J, Kang YJ. Disturbance of copper homeostasis is a mechanism for homocysteine-induced vascular endothelial cell injury. PLOS One 2013; 8 : e76209.